Zobrazeno 1 - 10
of 23
pro vyhledávání: '"T J Moss"'
Autor:
Kenneth J. Cohen, C. A. Long, S. Karandish, Moody D. Wharam, Donald Small, Michael B. Kastan, Charles N. Paidas, A. D. Friedman, Wing Leung, J. M. Davis, Michael J. Borowitz, S. J. Noga, T. J. Moss, Curt I. Civin, Cindy L. Schwartz, J. D. McMannis, R. C. Klann, Allen R. Chen
Publikováno v:
Bone Marrow Transplantation. 22:971-979
Many poor-risk neuroblastomas and tumours of the Ewing's sarcoma family (ET) recur despite autologous transplants. Recurrence may be due to tumor cells contained in the BM harvests or PBSC harvests. The objectives of this prospective study were to: (
Autor:
Howard M. Katzenstein, Paul R. Haut, Morris Kletzel, Elaine R. Morgan, T. J. Moss, Susan L. Cohn, M. Hoover, A. A. Green
Publikováno v:
Bone Marrow Transplantation. 20:543-551
A single institutional pilot study was conducted in which 12 poor-risk neuroblastoma (NB) patients were uniformly treated with multi-agent induction chemotherapy followed by myeloablative consolidation chemotherapy and unpurged peripheral blood stem
Autor:
J. M. Davis, M J Kennedy, A M Huelskamp, Nancy E. Davidson, S. L. Gerson, José Luís Passos-Coelho, T. J. Moss, Linda T. Vahdat, T. J. Layton, Amy A. Ross, Hillard M. Lazarus, K. Holland, Brenda W. Cooper, Karen H. Antman, Stefan Glück, S. J. Noga, A. Kaubish, A. B. Ostrander
Publikováno v:
Scopus-Elsevier
Autor:
J. M. Davis, Nancy E. Davidson, T J Moss, D J Kahn, José Luís Passos-Coelho, M J Kennedy, A A Ross, A M Huelskamp, S. J. Noga
Publikováno v:
Journal of Clinical Oncology. 14:2569-2575
PURPOSE To evaluate tumor-cell contamination of peripheral-blood progenitor-cell (PBPC) collections obtained after priming with granulocyte colony-stimulating factor (G-CSF). PATIENTS AND METHODS Immunocytochemical (ICC) and tumor clonogenic (TCA) as
Autor:
M J Kennedy, T J Moss, J. M. Davis, A A Ross, S. J. Noga, José Luís Passos-Coelho, A M Huelskamp, Nancy E. Davidson
Publikováno v:
Blood. 85:1138-1143
The effect of priming on occult tumor cell involvement of peripheral blood (PB) and PB progenitor cell (PBPC) collections is poorly characterized. Using sensitive immunocytochemistry (ICC) and tumor clonogenic assays (TCA) specific for epithelial-der
Autor:
T J Moss, D G Sanders
Publikováno v:
Journal of Clinical Oncology. 8:736-740
Tumor surveillance tests are used to detect relapse and to guide the clinician in making therapeutic changes. Identification of relapse early in the course of disease may improve long-term survival. For patients with neuroblastoma, current convention
Autor:
T J, Moss, R, Harding
Publikováno v:
Sleep research online : SRO. 1(1)
Our aim was to determine the effects of intrauterine compromise, induced by maternal anemia, on ventilatory responsiveness of the sleeping newborn to progressive asphyxia. We induced anemia in 6 sheep for the final third of pregnancy and studied thei
Autor:
Seth P. Harlow, Ned Z. Carp, T. A. Gaskin, David N. Krag, Takamura Ashikaga, Peter D. Beitsch, T. J. Moss, Frederick L. Moffat, Donald L. Weaver, J. W. Shook, Roberto Kusminsky, Sheldon Feldman, Thomas G. Frazier
Publikováno v:
The breast journal. 5(6)
The goal of this pilot study was to determine in patients with operable breast cancer the incidence of breast cancer cells present in the blood, the clearance rate after surgical resection of the primary tumor, and the incidence of patients with pers
Autor:
H J, Ma, N N, Sjak-Shie, R A, Vescio, M, Kaminsky, A, Mikail, M, Pold, K, Parker, M, Beksac, D, Belson, T J, Moss, C H, Wu, J, Zhou, L, Zhang, G, Chen, J W, Said, J R, Berenson
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(11)
Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus, has been implicated in the pathogenesis of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), multicentric Castleman's disease, and recently multiple myeloma (MM
Autor:
T J, Moss
Publikováno v:
Cancer metastasis reviews. 18(1)
With the advent of new therapeutic modalities, the treatment options for oncologists can vary greatly depending upon the aggressiveness of the patient's cancer. Patients may receive no therapy, adjuvant therapy, aggressive adjuvant therapy (taxane ba